New York-based Sellas Life Sciences Group has recruited Barbara Wood as executive vice president, general counsel and corporate secretary, reporting to president and CEO Angelos Stergiou. It is a new position at the company.
Wood most recently served as senior vice president, general counsel and secretary with Ophthotech Corporation, where she advised on commercial and collaborative agreements and transactions, securities laws compliance and key strategic and legal issues, according to Sellas.
Before joining Ophthotech in 2013, Wood served as senior vice president and general counsel at OSI Pharmaceuticals. Earlier in her career, she was a partner at Squadron Ellenoff, where she focused on M&A, biotechnology, licensing, securities and venture capital matters.
Sellas is a clinical-stage biopharmaceutical company billing itself as focused on novel cancer immunotherapies for a broad range of cancer indications
‘We are pleased to welcome Barbara to our executive team. Barbara has extensive experience both as a biotech executive and a corporate lawyer, along with valuable expertise in licensing, acquisitions, divestitures, collaborations, intellectual property and strategic corporate development as well as commercial matters, which will undoubtedly support the continued growth and success of Sellas,’ Stergiou says in a statement.
‘I am excited to join Sellas’ dynamic leadership team and look forward to contributing to the company’s growth at this critical time,’ Wood says in the announcement.
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
